Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

Marta Airoldi, Maria Rosaria Valerio, Vittorio Gebbia, Gabriella Moretti, Mariangela Ciccarese, Emanuela Romagnoli, Luca Clivio, Nicla La Verde, Mirco Pistelli, Filippo Montemurro, Vittorio Gebbia, Alessandra Fabi, Laura Biganzoli, Donata Sartori, Antonella Ferzi, Francesco Atzori, Giorgio Mustacchi, Paolo Marchetti, Ornella Garrone, Marina Elena CazzanigaGiancarlo Bisagni, Alberto Fumagalli, Lorenzo Gianni, Alessio Schirone, Daniele Generali, Mario Airoldi, Anna Turletti, Claudio Scavelli, Michela Maur, Salvatore Artale, Livio Blasi, Antonio Febbraro, Claudio Verusio, Mauro Porpiglia, Antonio Frassoldati, Michelino De Laurentiis, Patrizia Vici, Corrado Ficorella, Ferdinando Riccardi, Michela Donadio, Lucia Del Mastro, Alberto Zambelli, Paolo Pronzato, Maria Rosaria Valerio, Andrea Michelotti, Clara Natoli, Antonino Musolino, Valter Torri, Raffaella Palumbo, Daniele Santini, Monica Giordano, Giulia Valeria Bianchi, Lorenzo Livi, Lucia Mentuccia, Andrea M. Fumagalli, Daniele Santini, Gabriella Moretti, Luisa Gianni'

Risultato della ricerca: Article

Abstract

Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.
Lingua originaleEnglish
pagine (da-a)1-8
Numero di pagine8
RivistaDefault journal
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cita questo

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. / Airoldi, Marta; Valerio, Maria Rosaria; Gebbia, Vittorio; Moretti, Gabriella; Ciccarese, Mariangela; Romagnoli, Emanuela; Clivio, Luca; La Verde, Nicla; Pistelli, Mirco; Montemurro, Filippo; Gebbia, Vittorio; Fabi, Alessandra; Biganzoli, Laura; Sartori, Donata; Ferzi, Antonella; Atzori, Francesco; Mustacchi, Giorgio; Marchetti, Paolo; Garrone, Ornella; Cazzaniga, Marina Elena; Bisagni, Giancarlo; Fumagalli, Alberto; Gianni, Lorenzo; Schirone, Alessio; Generali, Daniele; Airoldi, Mario; Turletti, Anna; Scavelli, Claudio; Maur, Michela; Artale, Salvatore; Blasi, Livio; Febbraro, Antonio; Verusio, Claudio; Porpiglia, Mauro; Frassoldati, Antonio; De Laurentiis, Michelino; Vici, Patrizia; Ficorella, Corrado; Riccardi, Ferdinando; Donadio, Michela; Del Mastro, Lucia; Zambelli, Alberto; Pronzato, Paolo; Valerio, Maria Rosaria; Michelotti, Andrea; Natoli, Clara; Musolino, Antonino; Torri, Valter; Palumbo, Raffaella; Santini, Daniele; Giordano, Monica; Bianchi, Giulia Valeria; Livi, Lorenzo; Mentuccia, Lucia; Fumagalli, Andrea M.; Santini, Daniele; Moretti, Gabriella; Gianni', Luisa.

In: Default journal, 2019, pag. 1-8.

Risultato della ricerca: Article

Airoldi, M, Valerio, MR, Gebbia, V, Moretti, G, Ciccarese, M, Romagnoli, E, Clivio, L, La Verde, N, Pistelli, M, Montemurro, F, Gebbia, V, Fabi, A, Biganzoli, L, Sartori, D, Ferzi, A, Atzori, F, Mustacchi, G, Marchetti, P, Garrone, O, Cazzaniga, ME, Bisagni, G, Fumagalli, A, Gianni, L, Schirone, A, Generali, D, Airoldi, M, Turletti, A, Scavelli, C, Maur, M, Artale, S, Blasi, L, Febbraro, A, Verusio, C, Porpiglia, M, Frassoldati, A, De Laurentiis, M, Vici, P, Ficorella, C, Riccardi, F, Donadio, M, Del Mastro, L, Zambelli, A, Pronzato, P, Valerio, MR, Michelotti, A, Natoli, C, Musolino, A, Torri, V, Palumbo, R, Santini, D, Giordano, M, Bianchi, GV, Livi, L, Mentuccia, L, Fumagalli, AM, Santini, D, Moretti, G & Gianni', L 2019, 'Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies', Default journal, pagg. 1-8.
Airoldi, Marta ; Valerio, Maria Rosaria ; Gebbia, Vittorio ; Moretti, Gabriella ; Ciccarese, Mariangela ; Romagnoli, Emanuela ; Clivio, Luca ; La Verde, Nicla ; Pistelli, Mirco ; Montemurro, Filippo ; Gebbia, Vittorio ; Fabi, Alessandra ; Biganzoli, Laura ; Sartori, Donata ; Ferzi, Antonella ; Atzori, Francesco ; Mustacchi, Giorgio ; Marchetti, Paolo ; Garrone, Ornella ; Cazzaniga, Marina Elena ; Bisagni, Giancarlo ; Fumagalli, Alberto ; Gianni, Lorenzo ; Schirone, Alessio ; Generali, Daniele ; Airoldi, Mario ; Turletti, Anna ; Scavelli, Claudio ; Maur, Michela ; Artale, Salvatore ; Blasi, Livio ; Febbraro, Antonio ; Verusio, Claudio ; Porpiglia, Mauro ; Frassoldati, Antonio ; De Laurentiis, Michelino ; Vici, Patrizia ; Ficorella, Corrado ; Riccardi, Ferdinando ; Donadio, Michela ; Del Mastro, Lucia ; Zambelli, Alberto ; Pronzato, Paolo ; Valerio, Maria Rosaria ; Michelotti, Andrea ; Natoli, Clara ; Musolino, Antonino ; Torri, Valter ; Palumbo, Raffaella ; Santini, Daniele ; Giordano, Monica ; Bianchi, Giulia Valeria ; Livi, Lorenzo ; Mentuccia, Lucia ; Fumagalli, Andrea M. ; Santini, Daniele ; Moretti, Gabriella ; Gianni', Luisa. / Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. In: Default journal. 2019 ; pagg. 1-8.
@article{2e907fe10cf7467e9a3f8981919c199f,
title = "Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies",
abstract = "Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3{\%} in the whole population, 26.9{\%} in the patients with bone only, and 21.8 and 21.4{\%} in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.",
author = "Marta Airoldi and Valerio, {Maria Rosaria} and Vittorio Gebbia and Gabriella Moretti and Mariangela Ciccarese and Emanuela Romagnoli and Luca Clivio and {La Verde}, Nicla and Mirco Pistelli and Filippo Montemurro and Vittorio Gebbia and Alessandra Fabi and Laura Biganzoli and Donata Sartori and Antonella Ferzi and Francesco Atzori and Giorgio Mustacchi and Paolo Marchetti and Ornella Garrone and Cazzaniga, {Marina Elena} and Giancarlo Bisagni and Alberto Fumagalli and Lorenzo Gianni and Alessio Schirone and Daniele Generali and Mario Airoldi and Anna Turletti and Claudio Scavelli and Michela Maur and Salvatore Artale and Livio Blasi and Antonio Febbraro and Claudio Verusio and Mauro Porpiglia and Antonio Frassoldati and {De Laurentiis}, Michelino and Patrizia Vici and Corrado Ficorella and Ferdinando Riccardi and Michela Donadio and {Del Mastro}, Lucia and Alberto Zambelli and Paolo Pronzato and Valerio, {Maria Rosaria} and Andrea Michelotti and Clara Natoli and Antonino Musolino and Valter Torri and Raffaella Palumbo and Daniele Santini and Monica Giordano and Bianchi, {Giulia Valeria} and Lorenzo Livi and Lucia Mentuccia and Fumagalli, {Andrea M.} and Daniele Santini and Gabriella Moretti and Luisa Gianni'",
year = "2019",
language = "English",
pages = "1--8",
journal = "Default journal",

}

TY - JOUR

T1 - Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

AU - Airoldi, Marta

AU - Valerio, Maria Rosaria

AU - Gebbia, Vittorio

AU - Moretti, Gabriella

AU - Ciccarese, Mariangela

AU - Romagnoli, Emanuela

AU - Clivio, Luca

AU - La Verde, Nicla

AU - Pistelli, Mirco

AU - Montemurro, Filippo

AU - Gebbia, Vittorio

AU - Fabi, Alessandra

AU - Biganzoli, Laura

AU - Sartori, Donata

AU - Ferzi, Antonella

AU - Atzori, Francesco

AU - Mustacchi, Giorgio

AU - Marchetti, Paolo

AU - Garrone, Ornella

AU - Cazzaniga, Marina Elena

AU - Bisagni, Giancarlo

AU - Fumagalli, Alberto

AU - Gianni, Lorenzo

AU - Schirone, Alessio

AU - Generali, Daniele

AU - Airoldi, Mario

AU - Turletti, Anna

AU - Scavelli, Claudio

AU - Maur, Michela

AU - Artale, Salvatore

AU - Blasi, Livio

AU - Febbraro, Antonio

AU - Verusio, Claudio

AU - Porpiglia, Mauro

AU - Frassoldati, Antonio

AU - De Laurentiis, Michelino

AU - Vici, Patrizia

AU - Ficorella, Corrado

AU - Riccardi, Ferdinando

AU - Donadio, Michela

AU - Del Mastro, Lucia

AU - Zambelli, Alberto

AU - Pronzato, Paolo

AU - Valerio, Maria Rosaria

AU - Michelotti, Andrea

AU - Natoli, Clara

AU - Musolino, Antonino

AU - Torri, Valter

AU - Palumbo, Raffaella

AU - Santini, Daniele

AU - Giordano, Monica

AU - Bianchi, Giulia Valeria

AU - Livi, Lorenzo

AU - Mentuccia, Lucia

AU - Fumagalli, Andrea M.

AU - Santini, Daniele

AU - Moretti, Gabriella

AU - Gianni', Luisa

PY - 2019

Y1 - 2019

N2 - Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.

AB - Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.

UR - http://hdl.handle.net/10447/359852

UR - http://www.karger.com/brc

M3 - Article

SP - 1

EP - 8

JO - Default journal

JF - Default journal

ER -